ライフサイエンスコーパス: gp120

1 nd on the surface envelope glycoprotein-120 (gp120).

2 5 contacts the CD4-induced bridging sheet of gp120.

3 immunogenicity compared to gp120.

4 bodies targeting MPER or the surface subunit gp120.

5 d tier 1 neutralizing antibodies against the gp120.

6 etate and paclitaxel or HIV envelope protein gp120.

7 fection by blocking CCR5 engagement with HIV gp120.

8 hen transfected with a plasmid encoding HIV1-gp120.

9 ellular matrix proteins that copurified with gp120.

10 utralizing anti-V3 loop antibodies and HIV-1 gp120.

11 due 43 of CD4 (a phenylalanine) engages with gp120.

12 ific epitopes, including regions of gp41 and gp120.

13 he MPER within the native prefusion trimer [(gp120/41)(3)] are elusive and even contradictory, hinder

14 We report here that HIV-1 gp120, a neurotoxic protein that is specifically associa

15 nth 18 (group 4b) improved responses to both gp120 A244gD- D11 (p<0.0001) and gp120 MNgD- D11 (p=0.00

16 at month 15 (group 4a) improved responses to gp120 A244gD- D11 (p=0.0003), and boosting at month 18 (

17 on-Deltagamma NK cells but responded to anti-gp120 Ab and Gag peptides, whereas non-Deltagamma NK cel

18 Further studies elucidate that gp120 activates microglia by stimulating Wnt/beta-cateni

19 (gp120-Ad2F) boost regimen (i.n./i.m.

20 the adenovirus type 2 fiber binding domain (gp120-Ad2F), a mucosal targeting ligand, exhibited enhan

21 6HB stability to outcompete inhibitors, but gp120 adaptive mutations differed between these R5 and X

22 ix-helix bundle, but they selected different gp120 adaptive mutations.

23 r (ALVAC) together with an envelope protein (gp120) adjuvanted in alum.

24 ining LDV/I, and the precise determinants of gp120-alpha4beta7 binding are not fully defined.

25 ipeptide motif LDV/I, are thought to mediate gp120-alpha4beta7 binding.

26 tly contradictory observations regarding the gp120-alpha4beta7 interaction and offer new insights int

27 ombinant human fibronectin fragment mediated gp120-alpha4beta7 interactions similarly to CHO cell fib

28 l finding that fibronectins mediate indirect gp120-alpha4beta7 interactions.

29 HIV gp120 also increased TNFalpha, TNFRI, mitochondrial supe

30 Immunization with recombinant ALVAC/gp120 alum vaccine provided modest protection from human

31 -molecule CD4-mimetic compounds (CD4mc) bind gp120 and act as competitive inhibitors of gp120-CD4 eng

32 ix proteins can mediate interactions between gp120 and alpha4beta7 This suggests that the extracellul

33 human immunodeficiency virus type 1 (HIV-1) gp120 and block CD4-induced conformational changes requi

34 ed to be indispensable for proper folding of gp120 and for viral infectivity.

35 the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV

36 tions containing S532P substantially reduced gp120 and gp41 association, Env trimer stability, and in

37 or by introducing a disulfide bridge between gp120 and gp41 designated "SOS" (A501C/T605C).

38 disulfide bond (SOS) to covalently link the gp120 and gp41 ectodomain (gp41(ECTO)) subunits and a po

39 Our results delineate differences in both gp120 and gp41 subunits between functional membrane Env

40 Interactions between the gp120 and gp41 subunits of the human immunodeficiency vi

41 sting of a trimer of heterodimers containing gp120 and gp41 subunits that mediates virus entry and is

42 elope glycoprotein (Env) trimer, composed of gp120 and gp41 subunits, mediates viral entry into cells

43 tend to disintegrate into their constituent gp120 and gp41(ECTO) subunits.

44 We isolated Env (fully cleaved to gp120 and gp41) from the surface of expressing cells usi

45 consists of trimeric (gp160)(3) cleaved to (gp120 and gp41)(3), interacts with the primary receptor

46 imers but includes a covalent linker between gp120 and gp41, an engineered 201-433 disulfide bond, an

47 nd its surface envelope glycoproteins (Env), gp120 and gp41, have evolved immune evasion strategies t

48 and the envelope (Env) glycoprotein subunits gp120 and gp41.

49 Thus, both gp120 and MVAgp140 can augment potential protection of a

50 1 region contributes to the association with gp120 and regulates Env transitions from the unliganded

51 neurons (HPNs) with methamphetamine and HIV gp120 and Tat increase dynamin-related protein 1 (DRP1)-

52 h CD4-induced changes in the conformation of gp120 and the antibody binding site.

53 protection of a DNA/MVA vaccine by enhancing gp120 and V1/V2 antibody responses, whereas potential pr

54 ost immunogens enhanced the breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cy

55 Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of par

56 trimer on virions, including a surface unit (gp120) and a transmembrane unit (gp41) responsible for v

57 tor NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited

58 MVAgp120 prime/combined i.m. (gp120) and i.n.

59 phenomenon in the HIV envelope glycoprotein (gp120), and the V-gene that encodes B-cell receptors/ant

60 lly expressed in neurons, was upregulated by gp120, and knockout of the FKN receptor CX3CR1, which is

61 d by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteract

62 ed the modeling of glycans on the surface of gp120, and utilized continuum solvent-based loop predict

63 t peak immunogenicity, the magnitudes of the gp120- and V1V2-specific IgG responses were comparable b

64 e in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue

65 ed using beads coated with monomeric gp41 or gp120; anti-V2 MAbs were dominant compared to anti-V3 an

66 urther, surface staining with 324.6 and anti-gp120 antibodies showed that ASP and gp120 colocalize, s

67 with efficiency similar to that of the anti-gp120 antibody VRC01.

68 significantly higher plasma IgG response to gp120 antigens (all adjusted p<0.01) but not gp70 V1V2 a

69 IgG bAb response rates were 100% to 3 Env gp120 antigens in both trials.

70 ponse rates to the 3 primary vaccine-matched gp120 antigens were all above 90% at both peak timepoint

71 odel of perineural HIV envelope glycoprotein gp120 application onto the rat sciatic nerve to test the

72 n a neuropathic pain model of perineural HIV gp120 application onto the sciatic nerve, we found that

73 een, except a higher response rate to ZM96.C gp120 at month 18 versus month 12: 64.5% versus 1.6% (di

74 Our results show that 36D5 binds gp120 at the base of the V3 loop and suggest that the an

75 We identify the gp120 beta20-beta21 element as a major regulator of Env

76 usion of viral and host cell membranes after gp120 binding to host receptor CD4.

77 Our findings suggest that HIV-1 gp120 binding to the CD4 receptor is required for m(6)A

78 that vaccine-induced neutralizing antibody, gp120-binding antibody levels and immunodominant specifi

79 ein specific for both the CD4 and coreceptor gp120-binding sites.

80 ies demonstrated that HIV-1 envelope protein gp120 binds and signals through alpha4beta7 and that thi

81 When gp120 binds sequentially to the receptors CD4 and CCR5 o

82 go entry-related conformational changes when gp120 binds sequentially to the receptors, CD4 and CCR5,

83 uscularly (i.m.) administered MVAgp120 prime/gp120 boost to allow comparison of an i.m. immunization

84 entical modified vaccinia virus Ankara-prime/gp120-boost immunization regimens.

85 y responses, whereas potential protection by gp120, but not MVAgp140 boosts, may be further impacted

86 Interestingly, gp120, but not the MVAgp140 boost, increased peak CD4(+)

87 gG responses against a linear epitope in the gp120 C1 region of the HIV-1 envelope glycoprotein.

88 d gp120 and act as competitive inhibitors of gp120-CD4 engagement.

89 ified vaccinia Ankara-SIV (MVA-SIV), and HIV-gp120-CD4 fusion protein plus adjuvants, which consisten

90 three mAbs from mice immunized with selected gp120-CD4i fusion proteins and found that their footprin

91 , we found that mice immunized with selected gp120-CD4i fusion proteins have higher frequencies of ge

92 Thus, using gp120-CD4i fusion proteins with selective glycan deletio

93 Abs for masking nND epitopes, referred to as gp120-CD4i fusion proteins.

94 llular cytotoxicity (ADCC) responses against gp120-coated target cells were similar in rabbits and RM

95 nd anti-gp120 antibodies showed that ASP and gp120 colocalize, suggesting that ASP might become incor

96 built homology models of the three antibody-gp120 complexes, extended the sampling times for large b

97 The V3 loop of the gp120 component of the Env trimer contributes to the cor

98 e glycans are among the major targets on the gp120 component of the HIV envelope protein (Env) for br

99 included a recombinant HIV glycoprotein 120 (gp120) construct fused to a small portion of herpes simp

100 by engineering fusion proteins consisting of gp120 Core and one or two CD4-induced (CD4i) mAbs for ma

101 focused CD4bs Ab response than prototypical gp120 Core by serological analysis.

102 tructure of a fully glycosylated SIV(mac239)-gp120 core in complex with rhesus CD4 and the antigen-bi

103 SIV-gp120 core, rhesus CD4, and their complex could each be

104 The gp120-coreceptor interaction has previously been propose

105 ns of EVs, in particular of those that carry gp120, decreases viral infection of human lymphoid tissu

106 fferent heavily glycosylated HIV antigens, a gp120-derived mini-protein and a large, stabilized envel

107 Genetic changes in HIV gp120 determine viral interactions with chemokine recept

108 tly, the covalent coupling not only enhanced gp120-directed responses compared to soluble trimers, it

109 NYVAC-C-KC vectors and the protein component gp120 elicited high levels of T cell and humoral immune

110 earlier and higher area under the curve for gp120 Env binding, production of anti-V1/V2 and neutrali

111 Early administration of gp120 Env protein (groups T2 and T4) was associated with

112 Co-administration of gp120 Env protein components with DNA or NYVAC vectors d

113 tein; and T4 was two doses of DNA vector and gp120 Env protein followed by two doses of NYVAC vector

114 tion regimens that delayed administration of gp120 Env protein until the 3-month vaccination (groups

115 in followed by two doses of NYVAC vector and gp120 Env protein.

116 or followed by two doses of NYVAC vector and gp120 Env protein; and T4 was two doses of DNA vector an

117 or followed by two doses of NYVAC vector and gp120 Env protein; T2 comprised four doses of NYVAC vect

118 T2 comprised four doses of NYVAC vector and gp120 Env protein; T3 was two doses of DNA vector follow

119 n the second variable domain (V2) of the HIV gp120 envelope (Env) protein, suggesting this region as

120 calculate the binding affinities between the gp120 envelope glycoprotein of HIV-1 and three broadly n

121 Previous reports indicate that some HIV-1 gp120 envelope proteins bind to and signal through alpha

122 showed that it bound a highly conserved Env gp120 epitope.

123 rect blockade of the interaction between the gp120 exterior envelope glycoprotein and CD4; (ii) prema

124 rotein (Env) trimer, which consists of three gp120 exterior glycoproteins and three gp41 transmembran

125 elope glycoproteins (Env), a trimer of three gp120 exterior glycoproteins, and three gp41 transmembra

126 one or in combination with Env glycoprotein (gp120) followed by a co-delivered NYVAC and Env protein

127 and TV1; variable 1 and 2 [V1V2] regions of gp120 from strains TV1, 1086, and B.CaseA, as 1086 V1V2

128 ng antibody (bAb) responses to HIV antigens (gp120 from strains ZM96, 1086, and TV1; variable 1 and 2

129 gp120 fused to the adenovirus type 2 fiber binding domai

130 erved contacts with the N332gp120 glycan and gp120 GDIR peptide motif, but in a distinct Env-binding

131 This is the first report associating HIV-gp120 genotype to a pulmonary disease phenotype, as we u

132 ia and selected for viruses lacking the N448(gp120) glycan.

133 Our identification of gp120 glycopeptide-induced, T cell-specific immune respo

134 The binding of the HIV-1 gp120 glycoprotein to CD4 triggers conformational change

135 The engagement of the HIV-1 gp120 glycoprotein to the host CD4 protein triggers conf

136 sion, these results clarify the role of core gp120 glycosylation and illustrate a general method for

137 hieved, we immunized rabbits with B41 SOSIP (gp120-gp41 disulfide [SOS] with an isoleucine-to-proline

138 v trimers (sgp140 SOSIP.664) stabilized by a gp120-gp41 disulfide bond and a change (I559P) in gp41 h

139 and X4 viruses, providing new insights into gp120-gp41 functional interactions affecting Env refoldi

140 HIV-1) envelope glycoprotein (Env) trimer of gp120-gp41 heterodimers mediates virus entry into CD4-po

141 pe from HR1 peptide inhibition but different gp120-gp41 interactions to regulate Env conformational c

142 ies focused on the V2 and V3 regions and the gp120-gp41 interface, we developed the CZA97 SOSIP.v4.2-

143 CCR5 interactions, and two conformations of gp120-gp41 protomers (A and B protomers in AAB and ABB t

144 The HIV-1 envelope glycoprotein (Env) (gp120-gp41)(3) is the target for neutralizing antibodies

145 irus (HIV-1) envelope (Env) glycoprotein, a (gp120-gp41)(3) trimer, mediates fusion of viral and host

146 lycan shield covering the surface of the HIV gp120/gp41 envelope (Env) trimer, and how the glycan shi

147 he available three-dimensional structures of gp120/gp41 or their complexes with neutralizing antibodi

148 (HIV-1) envelope glycoprotein (Env) trimer, (gp120/gp41)(3) Soluble versions of HIV-1 Env trimers (sg

149 rotein [Env; trimeric (gp160)(3) cleaved to (gp120/gp41)(3)] attaches the virion to a susceptible cel

150 e viral envelope glycoprotein (Env) trimer [(gp120/gp41)(3)] binds the receptors CD4 and CCR5 and fus

151 e HIV-1 envelope glycoprotein (Env) trimer [(gp120/gp41)(3)] is a metastable complex expressed at the

152 e spike [Env; trimeric (gp160)3, cleaved to (gp120/gp41)3] poses challenges for vaccine development.

153 ope and a bNAb (87% breadth) directed to the gp120:gp41 interface, both resolved by high-resolution c

154 Similar to MAdCAM, the V2 domain of the gp120 HIV envelope protein binds to alpha(4)beta(7) In t

155 In the RV144 gp120 HIV vaccine trial, decreased transmission risk was

156 singly, vaccinated animals exhibited no anti-gp120 humoral responses above background and Gag- and En

157 immunization with gp120 to induce serum anti-gp120 IgG responses not significantly different than tho

158 Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen ca

159 The AE.A244 gp120 in AIDSVAX B/E also bound to the unmutated ancesto

160 ALVAC-SIV, with both given as a vector-prime/gp120 in alum boost strategy.

161 ectron microscopy structure of a full-length gp120 in complex with soluble CD4 and unmodified human C

162 titution increased the amount of dissociated gp120 in the cell culture supernatant.

163 bstantially increases the binding of 36D5 to gp120 in the intact Env trimer, consistent with CD4-indu

164 bic FP and recognizes a continuous region of gp120, including a conserved N-linked glycan at N88.

165 ures within the second variable loop (V2) of gp120, including the tripeptide motif LDV/I, are thought

166 tic terminals in cortex and hippocampus from gp120-induced damage.

167 n of Wnt/beta-catenin signaling blocked both gp120-induced FKN upregulation and synaptic degeneration

168 essor DKK1, or knockout of CX3CR1 alleviated gp120-induced mechanical allodynia in mice, suggesting a

169 tO2(.-)-pCREB triggers pC/EBPbeta in the HIV gp120-induced neuropathic pain state.

170 of the Wnt/beta-catenin/FKN/CX3R1 pathway to gp120-induced pain.

171 TIMBD inhibited gp120-induced RNA and protein expression levels of IL6 a

172 (both sexes), microglial ablation inhibited gp120-induced synapse decrease.

173 ellular FKN/CX3CR1 signaling plays a role in gp120-induced synaptic degeneration.

174 ressed in microglia, protected synapses from gp120-induced toxicity.

175 ese findings collectively suggest that HIV-1 gp120 induces synaptic degeneration in the spinal pain n

176 exposure to the HIV-related proteins Tat or gp120 induces TREM-1 expression in macrophages and confe

177 gnized by antibodies targeting the conserved gp120 inner domain and mediating ADCC.

178 work suggests that specific residues of the gp120 inner domain layers have coevolved with H375 in or

179 nti-cluster A family of Abs which target the gp120 inner domain, to bind and stabilize an asymmetric

180 utations increase hydrophobic packing at the gp120 inner-outer domain interface and were broadly appl

181 The V3 loop of gp120 inserts into the chemokine-binding pocket formed b

182 y, was specific for determinants at the gp41-gp120 interface.

183 nti-CoRBS and anti-cluster A Abs to the same gp120 is required for interaction with soluble dimeric F

184 The interaction between 36D5 and SIV gp120 is similar to the interaction between some broadly

185 The HIV envelope glycoprotein (gp120) is neurotoxic and has been linked to alterations

186 Shedding of gp120, known to severely complicate structural studies,

187 anti-HIV monoclonal antibodies (MAbs), anti-gp120 MAb 924 or anti-gp41 MAb 7B2.

188 Broadly neutralizing, anti-HIV-1 gp120 mAbs have been isolated from infected individuals,

189 displayed stronger activity than other anti-gp120 MAbs in screening against one of two gp120s and ag

190 igher-magnitude antibody levels than adults (gp120 median FIs of 15,509 [infants] and 2,290 [adults],

191 ts immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensities [FIs] in infants =

192 n important role in neuropathology caused by gp120, METH and NT, which are the major pathogenic facto

193 7 nAChR in up-regulation of Abeta induced by gp120, METH and NT.

194 Here, we hypothesized that Glycoprotein 120 (gp120), methamphetamine (METH) and nicotine (NT) can enh

195 t months 0 and 1 and with bivalent subtype C gp120/MF59 at months 3, 6, and 12.

196 evealing tyrosine-sulfated interactions with gp120 mimicking CCR5 interactions, and two conformations

197 ses to both gp120 A244gD- D11 (p<0.0001) and gp120 MNgD- D11 (p=0.0016).

198 nding uncleaved pseudotrimer and the matched gp120 monomer.

199 Env gp140 (native or uncleaved molecules) or gp120 monomeric proteins elicit relatively poor B-cell r

200 human immunodeficiency virus type 1 (HIV-1) gp120 (MVAgp120) prime and a HIV-1 gp120 protein boost c

201 vels of cellular RNA, which was reduced by a gp120-neutralizing antibody.

202 heir respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axis of the EV-A71 capsid)

203 , treatment of Jurkat cells with recombinant gp120 of HIV-1 Env significantly increased m(6)A levels

204 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV

205 protein, a V3 polypeptide derived from HIV-1 gp120, or a simple 9-fluorenylmethyl chloroformate-prote

206 These results demonstrate needle-free MVA/gp120 oral vaccination as a practical and effective rout

207 r tryptophan for serine 375 (S375H/W) in the gp120 Phe 43 cavity, where Phe 43 of CD4 contacts gp120,

208 did not depend upon the availability of the gp120 Phe 43 cavity.

209 e analogs of this family of CD4mc engage the gp120 Phe43 cavity by contacting the highly conserved D3

210 HIV protein gp120 plays a key role in the pathogenesis of HIV-PAH.

211 ertoire recognizes a glycopeptide epitope on gp120 presented by MHCII pathway.

212 vary (CHO) cells used to express recombinant gp120 produced fibronectins and other extracellular matr

213 th NYVAC-C-KC vectors plus the clade C HIV-1 gp120 protein (weeks 12 and 24).

214 1 (HIV-1) gp120 (MVAgp120) prime and a HIV-1 gp120 protein boost could be optimized to induce serum a

215 The gp120 protein boost elicited earlier and higher peak res

216 maintained upon boosting with gp145 DNA and gp120 protein coimmunization.

217 inia Ankara (MVA) and a recombinant trimeric gp120 protein generates strong vaccine-specific IgG resp

218 s by stabilizing a conformation of the virus gp120 protein not recognized by the host cell CD4 recept

219 scularly with ALVAC-SIV recombinant plus SIV gp120 protein or with DNA for SIV genes and rhesus inter

220 HVTN 100 tested ALVAC prime and ALVAC plus gp120 protein plus MF59 adjuvant boost (same protein/adj

221 tion device (Biojector) and DNA plasmid plus gp120 protein plus MF59 adjuvant boost.

222 nally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses.

223 e when administered together with adjuvanted gp120 protein.

224 SIV genes and rhesus interleukin-12 plus SIV gp120 protein.

225 ns and coadministration of purified bivalent gp120 proteins (AIDSVAX B/E).

226 of alpha4beta7 binding has been reported in gp120 proteins containing LDV/I, and the precise determi

227 (M766)Gag/Pro/gp120-TM and SIV(M766&CG7V) gD-gp120 proteins formulated in alum hydroxide (ALVAC/Env)

228 nterleukin 12 (IL-12) plus SIV(M766&CG7V) gD-gp120 proteins formulated in alum phosphate (DNA&Env).

229 resent glycosylation profiles of recombinant gp120 proteins from four major clades of HIV-1 (A, B, C,

230 son of glycosylation patterns of recombinant gp120 proteins from four major clades of HIV-1 produced

231 recombinants and boosted twice i.m. with SIV gp120 proteins in alum.

232 to mediate the binding of a diverse panel of gp120 proteins to alpha4beta7 in an in vitro cell bindin

233 nt bNAbs, enabling them to reach an adjacent gp120 protomer.

234 evious influenza infection, we also obtained gp120-reactive antibodies from non-HIV-infected donors,

235 Interestingly, none of the intersubtype gp120 recombinants recombined between C1 and gp41 region

236 utilize functional groups that interact with gp120 residues from the conserved beta20-beta21 hairpin

237 t month 12 (groups 2 and 3) did not increase gp120 responses compared with the peak responses after t

238 Phe 43 cavity, where Phe 43 of CD4 contacts gp120, results in the spontaneous sampling of an Env con

239 rent phylogenetic methods, we analyzed viral gp120 sequences obtained from extensive longitudinal sam

240 nv protomers were occupied by the CD4mc, and gp120 shedding from the Env trimer was increased in the

241 ciation, Env trimer stability, and increased gp120 shedding.

242 d to protein-boosted regimens, half-lives of gp120-specific antibodies were longer but peak magnitude

243 that vaccine adjuvants differently modulate gp120-specific antibody responses in adults and infants

244 ) T cells were significantly associated with gp120-specific B cell frequencies.

245 V antigen specificities were associated with gp120-specific B cell levels.

246 Furthermore, gp120-specific B cell transcriptomics from MVA-boosted a

247 ite controllers displayed greater amounts of gp120-specific B cells in the resting memory subset, whe

248 progressors, we found that a small subset of gp120-specific interleukin-21 (IL-21)-secreting CXCR5(+)

249 upregulation and synaptic degeneration, and gp120 stimulated Wnt/beta-catenin-regulated FKN expressi

250 will allow us to use our knowledge of HIV-1 gp120 structure and function, and the immune response ta

251 In the randomized cohort, glycoprotein 120 (gp120) substitutions were found in 20 of 47 patients (43

252 inant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31

253 6 to 10-1074 did not promote shedding of the gp120 subunit of Env.

254 Diverse entry inhibitors targeting the gp120 subunit of the HIV-1 envelope (Env) trimer have be

255 al State 2A stabilization requires all three gp120 subunits to be bound by both CD4mc and anti-CoRBS

256 us to show that State 2A requires all three gp120 subunits to be bound by sCD4/CD4mc and anti-CoRBS

257 Binding of the gp120 surface subunit of the envelope glycoprotein (Env)

258 e protein-protein interface for the antibody-gp120 system investigated previously and three additiona

259 Conversely TDF protected gp120-tg mice from cognitive dysfunction.

260 In the brains of wt and gp120-tg mice, TDF decreased expression of mitochondrial

261 glia in the hippocampi of TDF-treated wt and gp120-tg mice.

262 d decreased expression of IBA1 in the wt and gp120-tg mice.

263 interleukin (IL) 1beta and TNFalpha mRNA in gp120-tg mouse brains.

264 in to CD4 triggers conformational changes in gp120 that allow high-affinity binding to its coreceptor

265 4 protein triggers conformational changes in gp120 that allow its binding to co-receptors and is nece

266 CR5 induces no obvious allosteric changes in gp120 that can propagate to gp41; it does bring the Env

267 e-guided design of HIV-1 cyclically permuted gp120 that forms homogeneous, stable trimers, and displa

268 Furthermore, substitutions in gp120 that increased structural stability of Env (i.e. i

269 vestigate whether signature sequences in HIV-gp120 that predict tropism also predict PAH.

270 01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp1

271 he length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N

272 emically boosted with ALVAC-SIV(M766)Gag/Pro/gp120-TM and SIV(M766&CG7V) gD-gp120 proteins formulated

273 dependent on folding of the soluble subunit gp120 to a near-native conformation.

274 required for fibronectin-mediated binding of gp120 to alpha4beta7, nor did V2-specific antibodies blo

275 ired for intranasal (i.n.) immunization with gp120 to induce serum anti-gp120 IgG responses not signi

276 The capacity of the V2 domain of gp120 to mediate signaling through alpha(4)beta(7) likel

277 ant Env proteins shows rearrangements in the gp120 topological layer contacts with gp41.

278 TDF administered to wild-type (wt) and GFAP-gp120 transgenic (tg) mice caused peripheral neuropathy,

279 Moreover, HIV-1 infection or gp120 treatment did not alter the protein expression of

280 Differences were detected in the gp120 trimer association domain and C terminus and in th

281 sults suggest that cyclically permuted HIV-1 gp120 trimers represent a viable platform in which furth

282 that these drugs may antagonize HIV-1 Env at gp120 V1V2 to block viral membrane fusion.

283 ostimulation, cellular activation induced by gp120 V2 is inhibited by anti-alpha(4)beta(7) monoclonal

284 n, Env-specific CD4(+) T-cell responses, and gp120 V2 loop specific antibodies.

285 lpha(4)beta(7) In this study, we report that gp120 V2 shares with MAdCAM the capacity to signal throu

286 Among the latter are epitopes in the gp120 V3 region that are highly immunogenic when SOSIP t

287 into the dominant site for tier-1 NAbs, the gp120 V3 region, to block the induction of off-target an

288 infants with an MF59-adjuvanted recombinant gp120 vaccine induced higher-magnitude, potentially prot

289 and NF449 interfered with the ability of the gp120 variable regions 1 and 2 (V1V2)-targeted broadly n

290 to CD4 binding, with an outward movement of gp120-variable loops and an extension of a critical gp41

291 Limitations were that higher doses of gp120 were not evaluated, this study was not designed to

292 n D (gD) so that the first 40 amino acids of gp120 were replaced by the signal sequence and the first

293 rged in gp41 (62%) and C1 (25.3%) domains of gp120, which has strong correlation with the similarity

294 The N terminus of gp120, which is gripped by gp41 in the pre-fusion or CD4

295 n state epitopes in the HIV surface antigen, gp120, while not exposed on free particles, rapidly beco

296 s to maintain the noncovalent association of gp120 with gp41 and to evade the host antibody response

297 with antibodies (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity

298 hened the labile, noncovalent interaction of gp120 with the Env trimer, enhanced or maintained the bi

299 this Thr was critical for the association of gp120 with the virion and that amino acid substitution i

300 Multiple HIV models showed that recombinant gp120-X4 as well as infectious HIV-X4 remarkably increas